News

Quantum-Si (Nasdaq: QSI) announced that Liberate Bio has integrated the Platinum® Next-Generation Protein Sequencer™ (NGPS) into their platform for developing novel gene therapies. Liberate is using the sequencer's protein barcoding application to screen lipid nanoparticle delivery vehicles in vivo, enhancing the precision, speed, and efficiency of their gene therapy discovery and development efforts.

The Platinum enables advanced insights into the proteome, providing characterization of protein sequence and variation at single-amino acid resolution. Unlike alternative approaches such as mass spectrometry, it does not require expensive equipment or specialized expertise. The integration has already shown transformative potential, allowing Liberate to accelerate discovery and screening efforts with reduced costs and shortened timelines.